Scott Devoll Cramer, Ph.D.
Curriculum Vitae

Work Address Department of Pharmacology
University of Colorado, Denver
Anschutz Medical Center
12801 E. 17th Ave., L18-6117
Mail Stop 8303, PO Box 6511
Aurora CO 80045
PH 303-724-6276
FX 303-724-3663 (not confidential)
Scott.cramer@cuanschutz.edu

Education

Ph.D., Biology
University of California, Santa Cruz
June, 1992

BA, Biology
University of California, Santa Cruz
June, 1986

AA, Biology Major
Cabrillo Community College, Aptos, California
December, 1984

Research and Professional Experience

2012-Present	Full Professor with Tenure, Department of Pharmacology University of Colorado, Anschutz Medical Campus
2011-Present	Member, University of Colorado Cancer Center
2011-2016	Member, Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado, Anschutz Medical Campus
Fall 2016-2017	Acting Director of Graduate Studies Cancer Biology Training Program University of Colorado, Anschutz Medical Campus
2011-2016	Co-Director Hormone Related Malignancies Program Colorado Comprehensive Cancer Center
2011-2012	Visiting Professor, Department of Pharmacology University of Colorado, Anschutz Medical Campus
2010-2011	Full Professor with Tenure, Department of Cancer Biology

	Wake Forest University School of Medicine
2008-2011	Associate Member of the Center for Human Cancer Genetics Wake Forest University School of Medicine
2009-2011	Associate appointment in the Institute for Regenerative Medicine Wake Forest University School of Medicine
2007-2011	Associate Professor with Tenure, Department of Cancer Biology Wake Forest University School of Medicine
2004-2007	Associate Professor, Department of Cancer Biology Wake Forest University School of Medicine
1996-2004	Assistant Professor, Department of Cancer Biology Wake Forest University School of Medicine
1996-2011	Member, Comprehensive Cancer Center of Wake Forest University
1996-2011	Associate appointment in the Department of Urology Wake Forest University School of Medicine
1994	Research Scientist, Metra Biosystems Sunnyvale California
1994-1996	Postdoctoral Fellow Advisor: Donna Peehl Department of Urology, Stanford University School of Medicine Research Title: PTHrP and Prostate
1992-1994	Postdoctoral Fellow Advisor: David Feldman Endocrinology Division, Stanford University School of Medicine Research Title: Vitamin D and Prostate Cancer
1988-1992	Doctoral Research Advisor: Frank Talamantes Dissertation Title: Regulation of the Growth Hormone Receptor and Growth Hormone-Binding Protein during Pregnancy in the Mouse Department of Biology, University of California, Santa Cruz
1986-1988	Laboratory Assistant Principal Investigator: Satyabrata Nandi Cancer Research Laboratories Department of Zoology University of California, Berkeley

Awards/Scholarships/Fellowships

2010	Graduate Student Association Faculty Excellence Award Wake Forest University Graduate School of Arts and Sciences Hooding and Awards Ceremony- May 15, 2010
1996	Travel Award, 7th Prouts Neck Meeting on Prostate Cancer CaPCURE Foundation
1995-1996	Postdoctoral Fellowship Department of Urology Stanford University
1994	Young Investigator Travel Award Basic and Clinical Aspects of Prostate Cancer American Association for Cancer Research
1993	Histopathobiology of Neoplasia Education Award American Association for Cancer Research
1992-1995	National Research Service Award National Cancer Institute US Department of Health and Human Services Grant # 1-F32-CA59086
1992	Robert D. Plageman Memorial Fund Dean's Postdoctoral Fellowship Stanford University School of Medicine Grant # 1-HAA-260-94799
1988	U.C. Regents Fellowship University of California, Santa Cruz
1984	Santa Cruz County Teachers Association Education Scholarship Cabrillo College
1982	Don Medina Memorial Scholarship in Marine Biology Cabrillo College

Extramural Funding

Ongoing Research Support (as PI only)

1R01CA199741 (Cramer, PI)
NIH/NCI 07/01/15-06/30/20
CHD1 and MAP3K7 Coordinate Deletion in Aggressive ERG Negative Prostate Cancer.
The goal of this project it to interrogate signaling pathways altered in prostate cancer that harbors loss of both CHD1 and MAP3K7. Additional genetic alterations will be modeled using prostate stem cells and cell lines. The clinical significance of the loss of prediction of tumor aggressiveness and biochemical relapse will also be determined in a large patient cohort.

Role:PI

T32CA190216 (Cramer, Reyland, MPI's)
NIH/NCI 07/01/2016-06/30/2021
Training Program in Cancer Biology
The goals of this project are to provide training to graduate students and post-doctoral fellows in Cancer Biology.
Role: Co-PI

U01CA231978 (Cramer, Costello, MPI)
NIH/NCI 09/01/19-08/31/24
Systems Analysis of Aggressive Prostate Cancer Pathology
The goals of this project are to mine omic databases to correlate molecular features of tumors with patient outcome, functionally interrogate novel subtypes using a developmental stem cell model of prostate cancer, and to interrogate targetable therapeutic pathways using in vitro and in vivo models.

Pending Extramural Funding (as PI only)

Prior Extramural Funding (as PI only)

1R21CA187354-02 (Cramer, PI) 07/01/2015-06/30/2018
NIH/NCI
CHD1 and TAK1 Synthetic Lethality in Prostate Cancer
The aims of this study are to identify therapeutics that specifically target tumors with loss of CHD1 and/or MAP3K7. Aim 1) Clinical Therapeutics for Prostate Cancer with loss of CHD1 and MAP3K7. Aim 2)) Genome-wide Synthetic Lethal Screen for Prostate Cancer with loss of CHD1 and MAP3K7
Role: PI

1R21CA197887-01A1 (Thorburn, Cramer, MPIs)
NIH/NCI 12/01/15-11/30/17
Autophagy regulation of prostate tumor development
The goal of this project is to conduct exploratory studies to investigate the functional role of autophagy on the development of prostate tumors harboring different genetic alterations.
Role:Co-PI

R01CA150105 (Cramer, PI) 07/01/10-6/30/16
NIH
The prostate stem cell is a target of vitamin D chemoprevention
The aims of this study are to define the role of vitamin D as a chemopreventative agent for prostate cancer.
Role:PI

1R21CA173092 (Cramer, Davalos, Co-PI's) 09/17/12-8/31/15
National Institutes of Health, NCI
Isolation of Tumor Initiating Cells (TICs) using Contactless Dielectrophoresis

The aims of this study are to sort cells based on their electircate charges and characterize their tumor initiating capacity.
Role: Co-PI

R01CA129418 (Cramer, PI) 07/01/09-06/30/15
National Institutes of Health, NCI
Tak1, A novel prostate cancer tumor suppressor
The aims of this study are to characterize the role of Tak1 loss in prostate tumorigenesis
Role: PI

R01 CA101023-05 Cramer (PI) 09/30/04-01/30/10
National Institutes of Health, NCI
Vitamin D and Soy Isoflavone Inhibition of Prostate
The aims of this proposal are to dissection of the molecular mechanism of synergistic growth inhibition by vitamin D and soy.
Role: Principal Investigator

1 R21 DK069331-02 Cramer PI 04/01/05-03/31/07
National Institutes of Health, NIDDK
Mitochondrial GRHPR and Hyperoxaluria
The aims of this study are to identify the mitochondrial targeting sequence in GRHPR.
Role: Principal Investigator

R21 CA108625-03 Cramer (PI) 07/01/04-06/30/07
National Institutes of Health, NCI
Prostate Specific Antigen and Prostate Cancer Progression
The aims of this proposal are to determine the role of PSA in the etiology of prostate cancer.
Role: Principal Investigator

PC040973 Cramer: PI 12/01/04-11/30/07
Department of Defense
Vitamin D and Genistein Inhibition of Prostate Growth
The aims of this proposal were to genetically dissect the vitamin D and genistein signaling pathways in the prostate, in vivo and in vitro
Role: Principal Investigator (Funds returned due to overlap with funded R01)

R21DK060480-03 Cramer (PI) 04/01/02-11/30/04
National Institutes of Health, NIDDK
GRHPR Knockout Mouse as a Model of Hyperoxaluria
The aims of this proposal were to develop a knockout model of primary hyperoxaluria type II by targeted deletion of the GRHPR gene in mice.
Role: Principal Investigator

NCBC 2001-ARG-0004 (Cramer, PI) 08/01/01-6/31/03
North Carolina Biotechnology Center
Prostate Targeted Immunotoxin Gene Therapy
The aims of this proposal were to develop prostate-targeted immunotoxin vectors using an sFV against PSMA, to produce and characterize prostate killer T-lymphocytes, and test their efficacy in vitro and in vivo.

Role: Principal Investigator

R29 DK 52623-05 (PI, Cramer, SD) 6/1/97- 5/30/02
National Institutes of Health, NIDDK
PTHrP and Prostate Growth
The aims of this study were to assess the biological activities of prostate-derived PTHrP peptides on prostate and bone cells.
Role: Principal Investigator

Oxalosis Hyperoxaluria Foundation (Cramer, PI) 1/1/99-12/31/2000
Genetic Basis of Primary Hyperoxaluria Type II (PH2)
The Aims of this study were to clone the human GRHPR gene and identify mutations in PH2 patients.
Role: Principal Investigator Funding was terminated due to R01 funding for the same project

NCBC 9805-ARG-0005 (Cramer, PI) 8/1/98-2/28/00
North Carolina Biotechnology Center
Prostate Targeted Gene Therapy
The aims of this study were to use the PSA promoter to drive toxin gene therapy
Role: Principal Investigator

F32-CA59086 (Cramer, PI) 7/1/92-6/30/95
National Institutes of Health, NCI
Vitamin D and Prostate Cancer
The aims of the this study were to identify the mechanism of growth inhibition by vitamin D on prostate cancer cells
Role: Principal Investigator

Teaching Experience

Spring 2016-2019	Hypothesis Development and Experimental Design CANB 7680-Course Director
2013-2016	Cancer Biology Journal Club-Course Director CANB 7613-Course Director
2013-2015	Pharmacology Journal Club-Course Director PHCL 7613-Course Director
Fall 2008-2011	Advanced Cell Biology of Cancer CB717, Wake Forest University School of Medicine
2006-2007 Acad yr	Ethics in Science GRAD713, Wake Forest University School of Medicine
Spring 2004-2008	The Cell Biology of Cancer CB704, Wake Forest University School of Medicine

Spring 2006-2008	Special Studies in Small Group Teaching Techniques Wake Forest University School of Medicine
Fall 2004-2007	Tutorials in Cell Biology of Cancer CB702, Wake Forest University School of Medicine
1996-2005	Co-Director Cancer Biology Graduate Program, Director of Recruitment Wake Forest University School of Medicine
Spring 1998-2002	The Cell Biology of Breast and Prostate Cancer CB704, Wake Forest University School of Medicine
1998-2003	Medical Student Small Group Teaching, Phase 1B Wake Forest University School of Medicine
1998-2003	Standardized Patient Assessment (SPA) evaluations, Phase 1B Wake Forest University School of Medicine
Summer, 1994	Visiting Biology Lecturer, Endocrinology Bio 150 University of California, San Diego
Fall, 1990	Teaching Assistant, Human Biology University of California, Santa Cruz
Fall, 1989	Teaching Assistant, Vertebrate Endocrinology University of California, Santa Cruz
Winter, 1988	Teaching Assistant, Endocrinology Laboratory University of California, Santa Cruz
1984-1986	Tutor, Chemistry, Biology, and Physics Equal Opportunity Programs and Services Cabrillo College, Aptos, California

Trainees

Current

2019-Present	Gabriel Yette, Postdoctoral Fellow University of Colorado, Anschutz Medical Campus Research Project, Prostate Cancer Molecular Subtypes
2019-Present	Dannah Miller, Postdoctoral Fellow University of Colorado, Anschutz Medical Campus Research Project, Targeting necroptosis in MAP3K7 null prostate cancer
2017-Present	Lauren Jillson, Graduate Student, Cancer Biology Training Program University of Colorado, Anschutz Medical Campus

Research Project, Androgen signaling in prostate cancer with loss of CHD1/MAP3K7

Past

2017-2019 Satoshi Washino, Postdoctoral Fellow
University of Colorado, Anschutz Medical Campus
Research Project, Therapeutic targeting of CHD1/MAP3K7 null tumors
Current position: Assistant Professor of Urology, Jiichi Univeristy

2014-2018 Megan Goodall, Postdoctoral Fellow, Pharmacology
University of Colorado, Anschutz Medical Campus
Research Project, Autophagy in prostate cancer
Co-mentored with Andrew Thorburn

2012-2017 Leah Rider, Postdoctoral Fellow, Pharmacology
University of Colorado, Anschutz Medical Campus
Research Project, Tak1 and CHD1 in prostate cancer
Current: Medical Science Liaison, Midwest - Oncology Medical Affairs
EMD Serono/Merck

2016-2017 Jenette Joseph, Postdoctoral Fellow, Pharmacology
University of Colorado, Anschutz Medical Campus
Research Project, ERG+ Molecular Subtypes in Prostate Cancer
Current: Clinical Veterinarian

2009-2015 Lindsey Ulkus-Rodrigues, Graduate Student, Cancer Biology Program
Wake Forest University School of Medicine
Research Project: Functional Genetics of Prostate Cancer
Current: Postdoctoral Fellow- Novartis

2014 Jayden Durbin, Haxtun High School Student
Summer Research Project-Vitamin D regulation of prostatic acid phosphatase mRNA.
Current: Sophmore Regis University

2011-2014 Isabel Schlaepfer, Instructor, Pharmacology
University of Colorado, Anschutz Medical Campus
Research Project, Lipid Metabolism in Prostate Cancer
Current: Assistant Professor, Medical Oncology, CUDenver/AMC

2010-2013 Molishree Joshi, Postdoctoral Fellow, Pharmacology
University of Colorado, Anschutz Medical Campus
Research Project: Vitamin D chemoprevention in the prostate stem cell
Current Position-Scientific Manager-Functional Genomics Core
University of Colorado Cancer Center

2012-2013 Valerie Barton, Graduate Student, Cancer Biology

	University of Colorado, Anschutz Medical Campus Research Project, Use of Stem Cells to Model Prostate Cancer Genetics
2012-2013	Justine Masselli, Graduate Student, Pharmacology University of Colorado, Anschutz Medical Campus Research Project, Vitamin D and Prostate Cancer Masters Received, 8/2013
2011-2012	Min Wu, Postdoctoral Fellow, Pharmacology University of Colorado, Anschutz Medical Campus Research Project, Tak1 and Prostate Cancer Current: Postdoctoral Fellow, MD Anderson
2011-2012	Courtney von Bergen, Graduate Student, Pharmacology University of Colorado, Anschutz Medical Campus Research Project, Prostate Stem Cell Chemoprevention Masters Received, 7/2012
2010-2011	Adela Cimic, Postdoctoral Fellow, Cancer Biology Program Wake Forest University School of Medicine Research Project, Tak1 histopathology in prostate cancer Current Position: Assistant Professor-Stony Brook Medical College
2008-2010	Laura Hover, Undergraduate Student, Biology Wake Forest University Research Project: Prostate Cancer Stem Cells Current Position: Postdoctoral Fellow, St. Jude's Children's Research Hospital
2006-2011	Sophia Maund, Graduate Student, Cancer Biology Program Wake Forest University School of Medicine Research Project: Vitamin D Chemoprevention of Prostate Cancer Current Position: Scientist: Genentech
2006-2011	Min Wu, Graduate Student, Molecular Genetics Program Wake Forest University School of Medicine Research Project: Tak1 in prostate tumorigenesis Current: Post-doctoral Fellow, MD Anderson
2005-2007	Tatsuya Takayama, Postdoctoral Fellow, Cancer Biology Program Wake Forest University School of Medicine Research Project: Mitochondrial GRHPR Current Position- Professor of Urology, Jiichi University School of Medicine, Japan
2004-2010	Linara, Axanova, Graduate Student, Cancer Biology Program Wake Forest University School of Medicine

Research Project: Vitamin D and AKT Signaling
Current Position: Technology Asset Manager, U Penn

2004-2007 Wenhong Chen, Postdoctoral Fellow, Cancer Biology Program
Wake Forest University School of Medicine
Research Project: Pim 1, a novel prostate tumor oncogene
Current Position: Research Fellow, Radiation Biology WFUSM

2004-2006 Wendy W. Barclay, Postdoctoral Fellow, Cancer Biology Program
Wake Forest University School of Medicine
Research Project: Prostate Stem Cells
Current Position: Science Educator

2000-2004 Wendy W. Barclay, Graduate Student, Cancer Biology Program
Wake Forest University School of Medicine
Research Project: Vitamin D and Prostate
Current Position: Science Educator

1998-2003 Anuradha Rao, Graduate Student, Molecular Genetics Program
Wake Forest University School of Medicine
Thesis Subject: Vitamin D and Genistein Synergism
Current Position: Research Assistant Professor, Emory

Spring 2002 Gabrielle Saluda, Reynolds High School
Center for Excellence in Teaching, Research and Learning Awardee
Research Project: 1α hydroxylase expression in breast epithelial cells

2000-2001 John Steen, Mt. Tabor High School
Honors Project: p27 and Vitamin D

Fall 1999 Reginald Colin Brown, Carver High School
Center for Excellence in Teaching, Research and Learning Awardee
Research Project: Mutation Analysis by SSCP

1997-1999 David Ramsey, Undergraduate Student
Wake Forest University
Research Project: Recombinant Expression of PSA in Prostate

1998-1999 Charles Rosser, Urology Resident
Wake Forest University School of Medicine
Research Project: Chemotherapy for Metastatic Prostate Cancer
Current Position: Medical Director, Cedars Sinai

Junior Faculty Mentoring

2017-Present Cecelia Caino, Assistant Professor of Pharmacology
University of Colorado, Anschutz Medical Campus
Primary Faculty Mentor

2017-2018	Matt Sikora, Assistant Professor of Pathology University of Colorado, Anschutz Medical Campus Mentoring Committee Member
2014-2018	James Costello, Assistant Professor of Pharmacology University of Colorado, Anschutz Medical Campus Primary Faculty Mentor
2012-2016	Elaine Lam, Assistant Professor of Medical Oncology University of Colorado, Anschutz Medical Campus Informal Faculty Mentor
2014-2016	Erica Mandell, Assistant Professor, Pediatrics University of Colorado, Anschutz Medical Campus
Spring 2006-2011	Guangchao Sui, Assistant Professor of Cancer Biology Wake Forest University School of Medicine
Spring 2007-2011	John Wilkinson, Assistant Professor ob Biochemistry Wake Forest University School of Medicine
Fall 2009-2011	Tim Pardee, Assistant Professor of Hematology/Oncology Wake Forest University School of Medicine

Internal Committees, University of Colorado

2016-Present	Director of Postdoctoral Training Program in Cancer Biology (T32)
2016-2017	Cancer Biology Graduate Program Curriculum Committee
2017-2018	Chair, Faculty Promotions and Tenure Committee
2015-2018	Faculty Promotions and Tenure Committee
2016-2017	Admissions Committee, Cancer Biology Graduate Training Program-Ad hoc
2016-2017	Graduate School Core Curriculum Committee
2016-2017	Search Committee, Assistant Professor of Cancer Pharmacology
2017	Search Committee, Associate/Full Professor of Cancer Pharmacology
2014-2015	Comprehensive Exam Committee-Cancer Biology Training Program
2012-2015	Pharmacology Graduate Student Recruitment Committee
2011-2015	Co-Director, Hormone Related Malignancies Program, UC Cancer Center
2011-2015	Group Leader, Prostate Cancer Translational Working Group
2011-2013	Chair, Search Committee for Assistant Professor of Cancer Pharmacology
2011-2013	Graduate Training Committee, Pharmacology Training Program

Internal Committees, Wake Forest University

Committee for Undergraduate Medical Education	(1998-2011)
Intramural Research Support Committee	(2009-2011)
Graduate Council	(2009-2011)
Chair, Curriculum Committee, MCB Graduate Program	(2010-2011)
Chair, Honor Code Panel, Graduate School	(2008/2009)
Honor Code Panel, Graduate School	(2007-2009)
Admissions Committee, Cancer Biology Graduate Program	(1996-2007)
Animal Care and Use Committee	(2006-2009)
Admissions Committee, Undergraduate Medical Education	(2006-2007)
Radiation Safety Committee	(2004-2007)

Oncology Marketing Advisory Committee (1996-2000)
Biosafety Committee, Environmental Health and Safety (1997-2000)
Steering Committee, Research Base Grant (1998-2000)
Facilities Planning Committee, 4th Floor Nutrition Center (1998-2001)
GMP Biologics and Gene Therapy Production Facility Planning Committee (1998-2001)
Medical School Accreditation Committee (LCME), Basic Sci. Subcommittee (1999-2000)
Lead Scientist, Reverse Site Visit Team to FDA, GMP Production Facility (2000)
Site Visit Committee, LCME Accreditation (2001)
Strategic Planning Subcommittee for Graduate and Postdoctoral Education (2001-2002)
Faculty Forum (2001-2003)
Intramural Research Support Committee (2001-2004)
Co-director, Cancer Biology Graduate Program (1996-2005)
Dean's Task Force on Graduate Recruitment (2004-2005)
MD/PhD Steering Committee (2002-2005)

External Services

Grant Reveiws

2018/2019 (July) Adhoc, NCI-F09-F-series Training Awards Study Section
2018 (June) Adhoc, NIH Cancer Genetics Study Section
2016-2018 Chair, Scientific Advisory Board, Cancer League of Colorado
2011-Present Chair, Maryland Stem Cell Research Program, Panel 1
2010 Adhoc, Australian Prostate Cancer Research Fund
2005-Present Oxalosis Hyperoxaluria Foundation
2013-2017 Chartered Member, NIH Tumor Cell Biology Study Section
2014-2016 Scientific Advisory Board, Cancer League of Colorado
2015 (Sept) Adhoc, NCI Provocative Question 4 SEP
2012 (Sept) Adhoc, NIH Tumor Cell Biology Study Section
2011 (Sept) Adhoc, NIH Cancer Etiology Study Section
2010 (June) Member, NCI Spore in Skin and Prostate Cancers, ZRCA1 RPRB-M
2009-2010 Adhoc, NIH Cancer Molecular Pathology (CAMP) Study Section
2009 (March) NIH, SEP, ZRG1 ONC-M (02) M-Mechanisms of Tumor Initiation and Progression
2008 (Sept) Member, New York Stem Cell Research Program, Cancer Stem Cells
2008-2010 Maryland Stem Cell Research Program, TEDCO Panel
2007 (June) Member, NCI SPORE in lymphoma, Prostate, Breast, and Skin Cancers SEP
2007 (Feb) Member, Multidisciplinary Postdoctoral Training Panel, DOD Breast Program
2005-2010 Adhoc, NIH Molecular Oncology (MONC) Study Section
2005 (Feb8/9) NCI Chemoprevention Program Project Cluster Review
2004 (Dec 10) NIDDK Urology SEP
2002-2005 Member, Experimental Therapeutics 1 Study Section, DOD Prostate Program
2004-2005 Member, Cell Biology 3 Study Section, DOD Breast Cancer Concept Awards
2000 Member, Cell Biology 3 Study Section, DOD Breast Cancer Program
1997-2001 Ad Hoc Reviewer, Veterans Administration
1999-2001 Ad Hoc Reviewer, Virginia Commonwealth Development Grants
1998 Ad Hoc Reviewer, Indiana State Development Grants

Editorial Boards

2018-Present Molecular Cancer Research

External Committees

2002-2004 Advisory Committee for NIDDK-Sponsored Patient Registry for Hereditary Calcium Oxalate Kidney Stone Diseases

9 Aug 2002 Planning Meeting for NIDDK-Sponsored Patient Registry for Hereditary Calcium Oxalate Kidney Stone Diseases

2006-Present Scientific Advisory Council, Oxalosis Hyperoxaluria Foundation

Journal Reveiws

Science Translational Medicine
Molecular Cancer Research
eLife
Cancer Biology and Therapeutics
Endocrine Related Cancer
Human Pathology
Endocrinology
Journal of Clinical Endocrinology and Metabolism
Journal of Bone and Mineral Research
Urology
Molecular Genetics and Metabolism
Human Mutation
Molecular Cancer Therapeutics
Cancer Research
Oncogene
Nucleic Acids Research
Journal of Biological Chemistry

Professional Memberships

1994-Present American Association for Cancer Research

Invited Lectures

5th International Workshop on Primary Hyperoxaluria, March 12/13, 1999, Kappel (Zurich) Switzerland
Characterization of the PH2 Gene: Protein and Genomic Structure of D-Glycerate Dehydrogenase in Humans

Urolithiasis 2000, February 13-17, Cape Town, South Africa
Missense, Nonsense and Deletion Mutations in the GRHPR Gene from PH2 Patients

Oxalosis 2000: Concepts and Controversies (NIDDK), November 16-17, Columbia, MD.
Molecular Genetics of Primary Hyperoxaluria Type II

FASEB Summer Research Conferences 2002: August 3-9, Saxtons River Vt. Calcium Oxalate in Biological Systems.
The Molecular Genetics of the *GRHPR* Gene in Primary Hyperoxaluria Type II

Stanford University School of Medicine Urology Research Series February 24 2003
Genetic Contributions to Variation in Serum PSA

University of California, Berkeley, Prolactin Lunch Series February 28 2003
Mechanisms of Vitamin D Growth Inhibition in Human and Mouse Prostatic Cells

University of North Carolina, Charlotte, Department of Biology Seminar Series, October 31, 2003
Endocrine, Autocrine and Paracrine Regulation of Prostatic Cell Lineages

Oxalosis 2003, NIDDK Workshop, Annapolis, MD November 20-21 2003 Glyoxylate Reductase Enzyme

The Rock Society 2004, Gainesville Fl, Feb 21, 2004 Mitochondrial Glyoxylate Reductase

University of Nevada, Reno. July 2004, Prostate Stem Cells

7th International Workshop on Primary Hyperoxaluria. Mayo Clinic, Rochester Mn, October 8-10, 2004 Should Genotyping be Used to Screen for Primary Hyperoxaluria?

University of Texas, Southwestern Health Sciences, Dallas April 25, 2005 Endocrine, Autocrine and Paracrine Regulation of Prostate Stem Cell Growth and Differentiation.

University of Texas, Southwestern Health Sciences, Dallas April 26, 2005 Chronic Stoners: The Role of Mitochondria in Genetic Kidney Stone Disease

Medical University of South Carolina, Charleston, June 21, 2006, A prostate stem cell tumor progression model: The roles of pRB and PIM1

Medical University of South Carolina, Charleston, April 2, 2008, Tak1, a novel prostate tumor suppressor

Kansas University Medical Center, Kansas City, Kansas, June 30, 2009, The prostate stem cell as a model for prostate chemoprevention

Medical University of South Carolina, Charleston, SC Sept 2009, The prostate stem as a target for Vitamin D signaling.

University of Colorado Denver Cancer Center, Sept 29, 2010, The prostate stem cell as a model for chemoprevention: The role of Vitamin D.

University of Colorado, Anschutz Medical Campus, Department of Pharmacology, Dec 10 2010, Use of stem cells to model prostate cancer genetics.

American Institute for Cancer Research, Nov 3-4, 2011, Washington DC, Stem cells are a target of vitamin D chemoprevention.

Hamamatsu University Medical School, Dec 13, 2011, Hamamatsu Japan, Use of Stem Cells to model prostate cancer genetics

Teikyo University Medical School, Dec 15, 2011, Tokyo Japan, Vitamin D and Prostate Chemoprevention

Takeda Genome Urology, Dec 17, 2011, Four Seasons Hotel at Chinsan-So, Tokyo Japan, Molecular Pathways Targeted by Vitamin D Chemoprevention of the Stem Cell

14th Vitamin D Workshop, June, 2012, Houston. Vitamin Actions on the prostate Stem Cell

Gordon Research Conference-Hormone Dependent Cancers. July 2013 Loss of Tak1 and CHD1 collaborate to promote aggressive prostate cancer

Purdue University Oct 2013 Vitamin D chemoprevention of prostate cancer

University of Hawaii Cancer Center, April 4, 2014 Tak1 and CHD1 loss in aggressive prostate cancer

Tulane University, November 12, 2014 Disrupted lineage differentiation in prostate cancer driven by CHD1 and MAP3K7 deficiency

Mayo Clinic, Sept 15, 2015 Lethal-subtypes in prostate cancer: Loss of MAP3K7 and CHD1 drive a neuronal phenotype that is castrate resistant

University of Nebraska Medical Center Eppley Institute Seminar, October 23, 2015: Use of stem cells to define functional prostate tumor subtypes

University of Nebraska Medical Center, Department of Biochemistry and Molecular Biology, Nov 6, 2017 CHD1 and MAP3K7 loss drive neuroendocrine and castrate resistant prostate cancer

Prostate Cancer Foundation-Coffey Holden Seminar June-2018, Tissue recombination between mesenchyme and epithelial stem cells for studying drivers of tumor heterogeneity

Brown University-Annual Patholbiology Training Program Retreat Aug 28th, Targeting the Achilles Heel in ERG Translocation Negative (?) Prostate Cancer

Publications

Original Peer Reviewed Scientific Reports

1) Balakrishnan, A., **Cramer, S.D.**, Bandyopadhyay, G., Imagawa, W., Yang, J., Elias, J., Beattie, C., Das Gupta, T., and Nandi, S. **1988**. Differential proliferative response of linoleate in cultures of epithelial cells from normal human breast and fibroadenomas. Cancer Res. 49:857-862

2) **Cramer SD**, Barnard R, Engbers C, Thordarson G, and Talamantes F. **1992** A mouse growth hormone-binding protein RIA: Concentrations in maternal serum during pregnancy. Endocrinology 130:1074-1076

3) **Cramer SD**, Barnard R, Engbers C, Ogren L, and Talamantes F. **1992** Expression of the growth hormone receptor and growth hormone-binding protein during pregnancy in the mouse. Endocrinology 131:876-882

4) **Cramer SD**, Wong L, Kensinger R, Ogren L, Talamantes F. **1992** Regulation of the hepatic growth hormone receptor and serum growth hormone-binding protein during pregnancy in the mouse: Effects of litter size. Endocrinology 131:2914-2920

5) Barnard R, Thordarson G, Lopez M, Yamaguchi M, Edens A, **Cramer SD**, Ogren L, Talamantes F. **1994** Expression of GH-binding protein with hydrophilic C-terminus by the mouse placenta: Studies *in vivo* and *in vitro*. Journal of Endocrinology 140:125-135

6) Krishnan A, **Cramer SD**, Bringhurst R, Feldman D. **1995** Regulation of 1,25-Dihydroxyvitamin D_3 Receptors by Parathyroid Hormone in Osteoblastic Cells: Role of the Second Messenger Pathways. Endocrinology 136:705-712

7) Peehl DM, Wong ST, **Cramer SD**, Feldman D. **1995** Suramin, Hydrocortisone, and Retinoic Acid Modify Inhibitory Effects of 1,25-Dihydroxyvitamin D3 on Prostatic Epithelial Cells. Urologic Oncology 1:188-194

8) **Cramer SD**, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. **1996** Parathyroid Hormone Related Protein (PTHrP) is an Epidermal Growth Factor-Regulated Secretory Product of Human Prostate Epithelial Cells. Prostate 29:20-29

9) **Cramer SD**, Chen Z, Peehl DM. **1996** Prostate Specific Antigen Cleaves Parathyroid Hormone-Related Protein (PTHrP) in the PTH-Like Domain: Inactivation of PTHrP-Stimulated cAMP Accumulation in Mouse Osteoblasts. Journal of Urology 156:526-531

10) Peehl DM, Edgar MG, **Cramer SD**, Deftos LJ. **1997** Parathyroid Hormone-related Protein (PTHrP) is not an autocrine Growth Factor for Normal Prostatic Epithelial Cells. Prostate 31:47-52

11) **Cramer SD**, Ferree PM, Lin K, Milliner D, Holmes RP. **1999** The Gene Encoding Hydroxypyruvate Reductase is Mutated in Patients with Primary Hyperoxaluria Type II. Human Molecular Genetics 8:2063-2069

12) Baretto A, Schwartz GG, Woodruff R, **Cramer SD**. **2000** 25-Hydroxyvitamin D_3, the Prohormone of 1,25-Dihydroxyvitamin D_3, Inhibits the Proliferation of Primary Prostatic Epithelial Cells. Cancer Epidemiology, Biomarkers and Prevention: 9:265-270

13) Webster KE, Ferree PM, Holmes RP, **Cramer SD**. **2000** Identification of Missense, Nonsense and Deletion Mutations in Patients with Primary Hyperoxaluria Type II (PH2). Human Genetics: 107:176-185

14) Webster KE, **Cramer SD**. **2000** Genetic Basis of Primary Hyperoxaluria Type II (PH2). Molecular Urology: 4:355-363

15) Xu JF, Meyers DA, Sterling D, Zheng SL. Catalona WJ, **Cramer SD**, Bleecker ER, Ohar J. **2002** Association Studies of Serum PSA Levels and the Genetic Polymorphisms at the Androgen Receptor and Prostate-Specific Antigen Genes. Cancer Epidemiology Biomarkers and Prevention: 11:664-669

16) Rao A, Woodruff RD, Wade WN, Kute TE, **Cramer SD**, **2002** Synergistic Inhibition of Prostatic Epithelial Cell Growth by Genistein and Vitamin D. Journal of Nutrition: 132:3191-3194.

17) Wade WN, Kute T. Koumenis C, Willingham MC, **Cramer SD**. **2002** p27*Kip1* is Essential for the Antiproliferative Action of 1,25-dihydroxyvitamin D_3 in Primary but not Immortalized Mouse Fibroblasts. Journal of Biological Chemistry: 277:37301-37306.

18) Hawkins GA, **Cramer SD**, Zheng SL, Isaacs SD, Wiley KE, Chang BL, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J. **2002** Sequence Variants in the 1-α-Hydroxylase Gene Are Not Associated with Prostate Cancer Risk. Prostate: 53:175-178

19) O'Flaherty JT, Rogers LC, Chadwell BA, Owen JS, Rao A, **Cramer SD**, Daniel LW. **2002** 5(S)-Hydroxy-6,8,11,14-E,Z,Z,Z-eicostetraenoate Stimulates PC3 Cell Signaling and Growth by a Receptor-Dependent Mechanism. Cancer Research: 62:6817-6819

20) Rao A, Chang B-L, Hawkins G, Hu JJ, Rosser CJ, Hall, MC, Meyers DA, Xu JF, **Cramer SD**. **2003** Analysis of the G/A Polymorphism in the Androgen Response Element I of the PSA Gene and Its Interactions with Androgen Receptor Polymorphisms. Urology:61:864-869

21) **Cramer SD**, Chang B-L, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke R, Thomas LN, Bleeker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J. **2003** Association Between Genetic Polymorphism in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels. The Journal of the National Cancer Institute: 95: 1044-1053 See accompanying editorial in same issue.

22) Dunlap N, Schwartz GG, Eads D, **Cramer SD**, Sherk AB, John V, Koumenis C. **2003** 1α,25-dihydroxyvitamin D3 (Calcitriol) and its Analog, 19-nor-1α,25$(OH)_2D_2$, Potentiate the effects of Ionizing Radiation on Human Prostate Cancer Cells. British Journal of Cancer 89:746-759

23) Schwartz GG, Eads D, **Cramer SD**, Rao A, Willingham MC, Chen TC, Koumenis C. **2004** Pancreatic cancer cells express 25-Hydroxyvitamin D-1-[alpha]-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis: 25:1016-1026

24) Rao A, Coan A, Welsh J-E, Barclay WW, Koumenis C, **Cramer SD**. **2004** Vitamin D Receptor and p21/WAF1 are Targets of Genistein and 1,25-dihydroxyvitamin D_3 in Human Prostate Cancer Cells. Cancer Research: 64:2143-2147

25) Lockett KL, Hall MC, Xu J, Zheng SL, Chuang SC, Clark PE, **Cramer SD**, Lohman K, Hu JJ. **2004** The ADPRT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function. Cancer Research: 64:6344-6348

26) Ahmed M, **Cramer SD**, Lyles D. **2004** Matrix Protein Mutants of Vesicular Stomatitis Viruses as Potent and Safe Vectors for Prostate Tumor Therapy. Virology: 330:34-49

27) Baker PR, **Cramer SD**, Kennedy M, Assimos DG, Holmes RP. **2004** Glycolate and glyoxylate metabolism in Hep G2 cells. American Journal of Physiology: 287:C1359-65

28) Dallas SL, Zhao S, **Cramer SD**, Chen Z, Peehl DM, Bonewald LF. **2005** Preferential Production of Latent Transforming Growth Factor Beta-2 by Primary Prostatic Epithelial Cells and its Activation by Prostate Specific Antigen. Journal of Cellular Physiology: 202:361-370

29) Barclay WW, **Cramer SD 2005** Culture of Mouse Prostatic Epithelial Cells from Genetically Engineered Mice. Prostate: 63:291-298

30) Barclay WW, Woodruff RD, Hall MC, **Cramer SD**. **2005** A System for Studying Epithelial-Stromal Interactions Reveals Distinct Inductive Abilities of Stromal Cells from Benign Prostatic Hyperplasia and Prostate Cancer. Endocrinology: 146: 13-18, See accompanying editorial in same issue.

31) Thorburn J, Moore F, Rao A, Barclay WW, Thomas L, Grant K, **Cramer SD**, Thorburn A. **2005** Selective inactivation of a FADD-dependent apoptosis and autophagy pathway in immortal epithelial cells. Molecular Biology of the Cell: 16:1189-1199

32) Wansley EK, Dillon PJ, Gainey MD, Tam J, **Cramer SD**, Parks G. **2005** Growth Sensitivity of a Recombinant Simian Virus 5 P/V Mutant to Type I Interferon Differs Between Tumor Cell Lines and Normal Primary Cells. Virology: 335:131-144

33) O'Flaherty JT, Rogers L, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, **Cramer SD**, Morrow C. **2005** 5-Oxo-ETE Analogs and the Proliferation of Cancer Biochimica Biophysica ACTA: 1736:228-236

34) Knight J, Holmes RP, Milliner DS, Monico CG, **Cramer SD** **2006** Glyoxylate Reductase Activity In Blood Mononuclear Cells And The Diagnosis Of Primary Hyperoxaluria Type 2. Nephrology Dialysis Transplantation. 21:2292-2295

35) Takayama, T, Nagata M, Ozono S, Nonomura K, **Cramer SD 2007** A Novel Mutation in the GRHPR gene in a Japanese patient with primary hyperoxaluria type 2 Nephrology Dialysis Transplantation: 22:2371-2374

36) Liu W, Chang BL, **Cramer S**, Koty PP, Li T, Sun J, Turner AR, Von Kap-Herr C, Bobby P, Rao J, Zheng SL, Isaacs W, Xu J **2007** Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers Clinical Cancer Research: 13:5028-33

37) Barclay WW, Axanova, LS, Chen WH, Maund, SL, Soker, S, Lees CJ, **Cramer SD 2008** Characterization of Adult Prostatic Progenitor /Stem Cells Exhibiting Self-Renewal and Multilineage Differentiation: Stem Cells: 26:600-610

38) **Cramer SD**, Sun J, Zheng SL, Xu J, Peehl DM. **2008** Association of PSA promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiology Biomarkers and Prevention: 17:2451-2457

39) Levin-Iaina N, Dinour D, Romero L, Ron R, Brady RL, **Cramer SD**, Holtzman EJ. **2009** Late diagnosis of primary hyperoxaluria type 2 in the adult: Effect of a novel mutation in glyoxylate reductase hydroxypyruvate reductase (GRHPR) gene on enzymatic activity and molecular modeling. Journal of Urology: 181:2146-2151

40) Wiklund F, Zheng L, Sun J, Adami H-O, Lilja H, Hsu F-C, Stattin P, Adolfsson J, **Cramer SD**, Duggan D, Carpten JD, Chang B-L, Isaacs WB, Gronberg H, Xu J. **2009** Association of reported prostate cancer risk alleles with serum PSA levels among men without a diagnosis of prostate cancer. Prostate: 69:419-427

41) Chang B-L, **Cramer SD**, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Adolfson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Gronberg H, Xu J. **2009** Fine mapping association study and functional analysis implicate a SNP in *MSMB* at 10q11 as a causal variant for prostate cancer risk. Human Molecular Genetics: 18:1368-1375

42) Deng Z, Wan M, Cao P, Rao A, **Cramer SD**, Sui G. **2009** Yin Yang 1 regulates the transcriptional activity of the androgen receptor. Oncogene; 28:3746-3757

43) Axanova LS, Sui G, McCoy T, Chen YQ, **Cramer SD**, **2010** 1,25-dihydroxyvitamin D_3 and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate: 70: 1658-1671 PMID: 20583132

44) Cao P, Deng Z, Wan M, Huang W, **Cramer SD**, Xu J, Lei M, Sui G. **2010** MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Molecular Cancer, 9:108

45) Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, **Cramer SD**, Lilly MB, Kraft AS, **2010** Regulation of Skp2 levels by the Pim1 protein kinase. Journal of Biological Chemistry: 285:29128-29137 PMID: 20663873

46) Maund S, Barclay WW, Hover L, Hipp JD, Sui G, Fleet J, Thorburn A, **Cramer SD**, **2011** Interleukin-1 alpha mediates the anti-proliferative effects of 1,25 dihydroxyvitamin D3 in prostate progenitor/stem cells Cancer Research: 71:5276-5286

47) Salmanzadeh A, Romero L, Shafiee H, Gallo-Villanueva RC, Stremler MA, **Cramer SD**, Davalos, RV, **2012** Isolation of prostate tumor initiating cells (TICs) through their dielectric signature. Lab Chip:12:182-189 PMID: 22068834

48) Knight J, Holmes RP, **Cramer SD**, Takayama T, Salido E, **2012** Hydroxyproline Metabolism in Mouse Models of Primary Hyperoxaluria. American Journal of Physiology: 302:F688-693, PMID: 22189945

49) Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, **Cramer SD**, Thomas MJ, Perry DL, Edwards I, Mucci L, Sinnott J, Loda M, Sui G, Berquin I, Chen Y, **2012** Effect of Dietary Polyunsaturated Fatty Acids on Castration-resistant Pten-null Prostate Cancer, Carcinogenesis: 33:404-412 PMID: 22159221

50) Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Kim ST, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, **Cramer SD**, Vessella RL, Zheng SL, Grönberg H, Isaacs WB, Xu J. **2012** Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene: 31(35):3939-3948 PMID 22139082

51) Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals D, Sinrintrapun JS, McCoy TP, Sun J, Kim S-T, Liu W, Peehl DM, Xu J, **Cramer, SD 2012** Suppression of Tak1 promotes prostate tumorigenesis. Cancer Research, PMID: 22467172

52) Liu W, Xie CC, Thomas CY, Kim S-T, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, **Cramer SD**, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. **2013** Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer: 1;119:2405-2412. doi: 10.1002/cncr.27954

53) Maund SL, Shi L, **Cramer SD 2013** A role for Interleukin-1 alpha in the 1,25 dihydroxyvitamin D3 response in mammary epithelial cells. PLoS One. 2013 Nov 7;8(11):e81367. doi: 10.1371/journal.pone.0081367. PMID: 24244740

54) Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, **Cramer SD**, Agarwal C, Agarwal R. **2014** Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF-β2 Molecular Carcinogenesis. Feb 24. doi: 10.1002/mc.22135.

55) Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, **Cramer SD**. **2014** Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Molecular Cancer Therapeutics. 13:2361-71. doi: 10.1158/1535-7163.MCT-14-0183.

56) Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, **Cramer SD**, Serkova NJ, Eckel RH **2015** Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[^{18}F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. Molec Imaging Biol. 17:529-38, PMID: 25561013

57) Rodrigues, L., L. Rider, C. Nieto, L. Romero, A. Karimpour-Fard, M. Loda, M.S. Lucia, M. Wu, L. Shi, A. Cimic, J.S. Sirintrapun, R. Nolley, C. Pac, H. Chen, D.M. Peehl, J. Xu, W. Liu, J.C. Costello, and **Cramer SD 2015** Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Research. 75:1021-1034. doi: 10.1158/0008-5472.CAN-14-1596 PMID: 25770290

58) Yu, N., Puckett, S., Antonozzi, P., **Cramer, SD**., Lyles, D. **2015** Changes in susceptibility to oncolytic vesicular stomatitis virus during progression of prostate cancer. Journal of Virology: 89:5250-63 PMID: 25741004

59) Mandell E, Seedorf GJ, Ryan SL, Gien J, **Cramer SD**, Abman SH. **2015** Antenatal Endotoxin Disrupts Lung Vitamin D Receptor and 25-hydroxyvitamin D 1-alpha Hydroxylase Expression in the Developing Rat. Am J Physiol Lung Cell Mol Physiol. doi: 10.1152/ajplung.00253.2015. [Epub ahead of print] PMID: 26342089

60) Goodall ML., Fitzwalter B., Zahedi S., Wu M., Rodriguez D., Mulcahy-Levi JM., Green, DR., Morgan M., **Cramer SD***., Thorburn A*. **2016** The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis. Developmental Cell: 337-49. doi: 10.1016/j.devcel.2016.04.018. PMID: 27219062 * These authors share senior authorship

61) Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, D'Agostino RB, Miller LD, Sirintrapun SJ, **Cramer SD**, Kridel SJ. **2018** CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Mol Cancer Res: 16:1687-1700 doi: 10.1158/1541-7786.MCR-17-0526

62) Ormond DR, Kleinschmidt-DeMasters BK, Cavalcante D, Smith EE, **Cramer SD**, Lucia MS. **2019** Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression. J Neurooncology 2019 Jan 17. doi: 10.1007/s11060-019-03099-x. [Epub ahead of print]

63) Washino S, Rider LC, Romero L, Jillson LK, Affandi T, Ohm AM, Lam ET, Reyland ME, Costello JC, **Cramer SD**. 2019 Loss of MAP3K7 sensitizes prostate cancer cells to CDK1/2 inhibition and DNA damage through disruption of homologous recombination: Molecular Cancer Research: **DOI:** 10.1158/1541-7786.MCR-18-1335

63) Rider LC, Rodrigues LU, Karimpour-Fard A, Romero L, Nieto C, Gillette C, Jillson L, Costello JC, **Cramer SD**. 2019 MAP3K7 and CHD1 loss drives both androgen receptor hyperactivity: In revision

Books

1) **Scott D. Cramer**. **2007** Deadly Diseases and Epidemics: Prostate Cancer, Chelsea New York Medicine and Health/Ferguson/Checkmark Books

2) **Scott D. Cramer (editor). 2013** Stem Cells and Prostate Cancer, Springer, New York

Book Chapters

1) **Scott D. Cramer** and Frank Talamantes **1992** The Growth Hormone Receptor and Growth Hormone-Binding Protein: Structure, Functions, and Regulation. In "The Endocrinology of Growth, Development, and Metabolism in Vertebrates" Peter K.T. Pang and Martin Schreibman, eds. New York: Academic Press. pp. 117-149

2) **Scott D. Cramer** and Tatsuya Takayama **2009** Primary Hyperoxaluria Chapter 33 In "Genetic Diseases of the Kidney" Richard Lifton, Stefan Somlo, Gerhard Giebisch, and Donald Seldin eds. San Diego CA, Elsevier Inc. pp. 571-586

3) Sophia L. Maund and **Scott D. Cramer 2009** "Translational implications of stromal-epithelial interactions in prostate cancer and the potential role of prostate cancer stem/progenitor cells" In "The Handbook of Cell Signaling" Second Edition, Ralph Bradshaw and Edward Dennis eds. San Diego CA, Elsevier Inc. :Vol 3, Chapter 323, 2773-2782

4) Sophia L. Maund and **Scott D. Cramer 2011** The role of vitamin D in the prevention and treatment of prostate cancer In "Prostate Cancer - From Bench to Bedside ISBN 978-953-308-80-6, Philippe E. Spiess Ed., Rijeka, Croatia, InTECH, Free online access at www.intechopen.com

5) Molishree Joshi, Courtney von Bergen, **Scott D Cramer 2013** "Targeting the Prostate Stem Cell for Chemoprevention" In: "Stem Cells and Prostate Cancer" Scott D. Cramer, ed. New York, Springer: Chapter 8: In Press

6) Lindsey Ulkus, Min Wu, **Scott D Cramer 2013** "Stem Cell Models for Functional Validation of Prostate Cancer Genes" In: "Stem Cells and Prostate Cancer" Scott D. Cramer, ed. New York, Springer: Chapter 9: In Press

Reviews

1) Maund SL, **Cramer SD**, **2010** The tissue-specific stem cell as a target for chemoprevention. Stem Cell Rev. 7:307-314 PMID: 21086069

2) Nieto CM, Rider LC, **Cramer SD**. **2014** Influence of epithelial-stromal interactions in androgen action. Endocrine Related Cancer. 2014 Aug;21(4):T147-60. doi: 10.1530/ERC-14-0138. Epub 2014 May 28. PMID: 24872510

Commentaries/Editorials

1) Sophia L. Maund and **Scott D. Cramer 2011** Pancreatic Cancer with Nest-in Tendencies: Cancer Biology and Therapeutics. E-Pub ahead of print: PMID: 21266845

2) Leah Rider and Scott D. Cramer 2015 SPOP the Mutation Elife 4. pii: e11760.

doi: 10.7554/eLife.11760. PMID: 26506153

3) Megan L. Goodall, **Scott D. Cramer** and Andrew Thorburn Autophagy Complexes Cell Death by Necroptosis. Oncotarget. 2016 doi: 10.18632/oncotarget.10640. [Epub ahead of print] PMID: 27449298

4) Megan L. Goodall, **Scott D. Cramer** and Andrew Thorburn Autophagy RIPs into Cell Death. Cell Cycle. 2016 Nov 16;15(22):3014-3015.
PMID: 27574850

Patents

1) Cramer SD, Rao A, Xu J, Chang B-L, Genetic polymorphisms in the prostate specific antigen gene. 2010, US patent number 12/720,818